Women’s Health NAMS Menopause Study Guide | Certified Menopause
Practitioner Prep NCMP Exam Study Guide – NAMS Certification for
Women’s Health Providers
What’s Inside:
✔️ Key concepts in menopause and perimenopause care
✔️ Evidence-based hormone therapy (HRT) guidelines
✔️ Non-hormonal therapies for vasomotor and genitourinary symptoms
✔️ Clinical case studies and sample scenarios
✔️ Practice questions aligned with NCMP test objectives
✔️ Covers bone health, cardiovascular risk, cancer screening, and more
✔️ Updated for 2024–2025 NCMP exam blueprint
🎯 Perfect for:
Women’s Health NPs & PAs
OB/GYNs & Primary Care Providers
Nurses preparing for NCMP certification
Anyone seeking a trusted, concise menopause resource
Physiology of Menopause
Overview of Menopause
Menopause typically occurs in women aged 40-58 years, with an average life expectancy
of 81.2 years.
The STRAW+10 classification is the gold standard for characterizing reproductive aging,
consisting of 7 stages: 5 before menopause and 2 after the final menstrual period (FMP).
The term 'perimenopause' refers to the transitional phase leading up to menopause,
characterized by endocrinologic, somatic, and psychological changes.
Terminology Related to Menopause
, Climacteric: Refers to the period of life during which a woman transitions to menopause.
Induced Menopause: Cessation of menses due to surgical removal of ovaries or
iatrogenic causes such as chemotherapy.
Premature Ovarian Failure: Menopause occurring before age 40, also known as
primary ovarian insufficiency.
Stages of Reproductive Aging
At birth, females have approximately 1-2 million oocytes, which decrease to 300,000-
500,000 at puberty.
Only about 400-500 oocytes will be ovulated during a woman's reproductive life.
The reproductive stages include early (-5), peak (-4), and late (-3a and -3b), with specific
hormonal profiles for each stage.
Menopause Transition Stages
The menopause transition consists of two stages: early (-2) and late (-1) menopause
transition, characterized by changes in cycle length and hormonal fluctuations.
The LOOP event describes a physiological phenomenon during the menopause transition
where elevated FSH leads to the recruitment of additional follicles, resulting in elevated
estradiol levels.
Hormonal Changes and Laboratory
Assessments
Hormonal Dynamics During Menopause
The primary driver of changes in the hypothalamic-pituitary-ovarian (HPO) axis during
menopause transition is follicular depletion, which begins before birth.
Inhibin B and AMH play crucial roles in regulating the follicle pool, with their decline
leading to increased FSH levels and subsequent follicle recruitment.
Laboratory Assessments for Menopause
FSH and estradiol (E2) should be assessed together to evaluate menopause status, as
elevated E2 can suppress FSH levels, leading to falsely normal results.
, AMH is a better predictor of menopause compared to FSH, as it reflects the ovarian
reserve more accurately.
Postmenopausal Hormonal Levels
In postmenopausal women, estradiol levels typically range from 10 pg/mL to 25 pg/mL,
indicating low ovarian function.
The stabilization of FSH and E2 levels occurs in the years following menopause,
particularly during the early postmenopausal phase.
Adrenal Physiology and Primary Ovarian
Insufficiency
Adrenal Hormones and Menopause
DHEAS is a precursor hormone that converts to androgens and estrogens in peripheral
tissues, with levels decreasing in the early to mid-20s.
Supplementation with DHEA is not recommended due to lack of evidence supporting
long-term safety, although topical applications may alleviate vaginal pain.
Primary Ovarian Insufficiency (POI)
POI is characterized by hypergonadotropic hypogonadism in women under 40, affecting
approximately 1% of women by this age.
Turner Syndrome is the most common genetic disorder associated with POI, occurring in
1 in 2,500 to 3,000 births, with 99% resulting in miscarriage.
Treatment and Management of POI
Hormone therapy is recommended for women with POI until the average age of
menopause to mitigate long-term effects of estrogen deficiency.
In cases of delayed puberty due to Turner Syndrome, estrogen replacement should begin
at age 12, with gradual increases to a target dose of 100 mcg.
Turner Syndrome and Hormonal Treatments
Estradiol Treatment in Turner Syndrome
, Recommended treatment involves transdermal estradiol (E2) at gradually increasing
doses over 2 years, targeting a final dose of 100 mcg.
This method is preferred due to its effectiveness in mimicking physiological hormone
levels and minimizing side effects.
The gradual increase helps the body adjust to hormone levels, reducing the risk of
adverse reactions.
Monitoring is essential to ensure the target dose is reached without complications.
Case studies show improved secondary sexual characteristics and bone density in patients
receiving this treatment.
Role of Progesterone in Treatment
Progesterone is added to the treatment regimen at the onset of menarche to regulate
menstrual cycles.
This addition is crucial for women who have achieved adequate estrogen levels to ensure
endometrial protection.
The timing of progesterone introduction is critical for optimal reproductive health
outcomes.
Historical context: The use of progesterone has evolved with a better understanding of
hormonal balance in women with Turner Syndrome.
Goals of Hormonal Treatment
The primary goals include the development of secondary sex characteristics such as
breast development and menstrual regularity.
Maximizing bone density is crucial to prevent osteoporosis, a common concern in Turner
Syndrome patients.
Hormonal treatments aim to improve quality of life and psychological well-being by
addressing hormonal deficiencies.
Long-term monitoring is necessary to adjust treatment as the patient ages and their needs
change.
Duration of Hormonal Therapy
Hormonal therapy should continue until the patient reaches an appropriate age for
menopause, typically around 50 years.
Practitioner Prep NCMP Exam Study Guide – NAMS Certification for
Women’s Health Providers
What’s Inside:
✔️ Key concepts in menopause and perimenopause care
✔️ Evidence-based hormone therapy (HRT) guidelines
✔️ Non-hormonal therapies for vasomotor and genitourinary symptoms
✔️ Clinical case studies and sample scenarios
✔️ Practice questions aligned with NCMP test objectives
✔️ Covers bone health, cardiovascular risk, cancer screening, and more
✔️ Updated for 2024–2025 NCMP exam blueprint
🎯 Perfect for:
Women’s Health NPs & PAs
OB/GYNs & Primary Care Providers
Nurses preparing for NCMP certification
Anyone seeking a trusted, concise menopause resource
Physiology of Menopause
Overview of Menopause
Menopause typically occurs in women aged 40-58 years, with an average life expectancy
of 81.2 years.
The STRAW+10 classification is the gold standard for characterizing reproductive aging,
consisting of 7 stages: 5 before menopause and 2 after the final menstrual period (FMP).
The term 'perimenopause' refers to the transitional phase leading up to menopause,
characterized by endocrinologic, somatic, and psychological changes.
Terminology Related to Menopause
, Climacteric: Refers to the period of life during which a woman transitions to menopause.
Induced Menopause: Cessation of menses due to surgical removal of ovaries or
iatrogenic causes such as chemotherapy.
Premature Ovarian Failure: Menopause occurring before age 40, also known as
primary ovarian insufficiency.
Stages of Reproductive Aging
At birth, females have approximately 1-2 million oocytes, which decrease to 300,000-
500,000 at puberty.
Only about 400-500 oocytes will be ovulated during a woman's reproductive life.
The reproductive stages include early (-5), peak (-4), and late (-3a and -3b), with specific
hormonal profiles for each stage.
Menopause Transition Stages
The menopause transition consists of two stages: early (-2) and late (-1) menopause
transition, characterized by changes in cycle length and hormonal fluctuations.
The LOOP event describes a physiological phenomenon during the menopause transition
where elevated FSH leads to the recruitment of additional follicles, resulting in elevated
estradiol levels.
Hormonal Changes and Laboratory
Assessments
Hormonal Dynamics During Menopause
The primary driver of changes in the hypothalamic-pituitary-ovarian (HPO) axis during
menopause transition is follicular depletion, which begins before birth.
Inhibin B and AMH play crucial roles in regulating the follicle pool, with their decline
leading to increased FSH levels and subsequent follicle recruitment.
Laboratory Assessments for Menopause
FSH and estradiol (E2) should be assessed together to evaluate menopause status, as
elevated E2 can suppress FSH levels, leading to falsely normal results.
, AMH is a better predictor of menopause compared to FSH, as it reflects the ovarian
reserve more accurately.
Postmenopausal Hormonal Levels
In postmenopausal women, estradiol levels typically range from 10 pg/mL to 25 pg/mL,
indicating low ovarian function.
The stabilization of FSH and E2 levels occurs in the years following menopause,
particularly during the early postmenopausal phase.
Adrenal Physiology and Primary Ovarian
Insufficiency
Adrenal Hormones and Menopause
DHEAS is a precursor hormone that converts to androgens and estrogens in peripheral
tissues, with levels decreasing in the early to mid-20s.
Supplementation with DHEA is not recommended due to lack of evidence supporting
long-term safety, although topical applications may alleviate vaginal pain.
Primary Ovarian Insufficiency (POI)
POI is characterized by hypergonadotropic hypogonadism in women under 40, affecting
approximately 1% of women by this age.
Turner Syndrome is the most common genetic disorder associated with POI, occurring in
1 in 2,500 to 3,000 births, with 99% resulting in miscarriage.
Treatment and Management of POI
Hormone therapy is recommended for women with POI until the average age of
menopause to mitigate long-term effects of estrogen deficiency.
In cases of delayed puberty due to Turner Syndrome, estrogen replacement should begin
at age 12, with gradual increases to a target dose of 100 mcg.
Turner Syndrome and Hormonal Treatments
Estradiol Treatment in Turner Syndrome
, Recommended treatment involves transdermal estradiol (E2) at gradually increasing
doses over 2 years, targeting a final dose of 100 mcg.
This method is preferred due to its effectiveness in mimicking physiological hormone
levels and minimizing side effects.
The gradual increase helps the body adjust to hormone levels, reducing the risk of
adverse reactions.
Monitoring is essential to ensure the target dose is reached without complications.
Case studies show improved secondary sexual characteristics and bone density in patients
receiving this treatment.
Role of Progesterone in Treatment
Progesterone is added to the treatment regimen at the onset of menarche to regulate
menstrual cycles.
This addition is crucial for women who have achieved adequate estrogen levels to ensure
endometrial protection.
The timing of progesterone introduction is critical for optimal reproductive health
outcomes.
Historical context: The use of progesterone has evolved with a better understanding of
hormonal balance in women with Turner Syndrome.
Goals of Hormonal Treatment
The primary goals include the development of secondary sex characteristics such as
breast development and menstrual regularity.
Maximizing bone density is crucial to prevent osteoporosis, a common concern in Turner
Syndrome patients.
Hormonal treatments aim to improve quality of life and psychological well-being by
addressing hormonal deficiencies.
Long-term monitoring is necessary to adjust treatment as the patient ages and their needs
change.
Duration of Hormonal Therapy
Hormonal therapy should continue until the patient reaches an appropriate age for
menopause, typically around 50 years.
